Liposomes as a Novel Ocular Delivery System for Brinzolamide: In Vitro and In Vivo Studies


The objective of this study was to investigate the potential of liposomes as an ophthalmic delivery system for brinzolamide (Brz) to enhance the local glaucomatous therapeutic effect. The liposomes of Brz (Brz-LPs) were produced by the thin-film dispersion method with a particle size of 84.33 ± 2.02 nm and an entrapment efficiency of 98.32 ± 1.61%. Differential scanning calorimetry (DSC) and X-ray powder diffraction (XRD) analysis proved that Brz was successfully entrapped into Brz-LPs. Brz-LPs displayed a biphasic release pattern in vitro with burst release initially and sustained release afterwards. The corneal permeability was measured using modified Franz-type diffusion cells, and Brz-LPs showed 6.2-fold increase in the apparent permeability coefficient when compared with the commercial available formulation (B rz-Sus). Moreover, Brz-LPs (1 mg/mL Brz) showed a more sustained and effective intraocular pressure reduction (5–10 mmHg) than Brz-Sus (10 mg/mL Brz) in white New Zealand rabbits. Therefore, Brz-LPs were a hopeful formulation of Brz for glaucoma treatment and worthy of further investigation.

DOI: 10.1208/s12249-015-0382-1

Extracted Key Phrases

8 Figures and Tables

Cite this paper

@article{Li2015LiposomesAA, title={Liposomes as a Novel Ocular Delivery System for Brinzolamide: In Vitro and In Vivo Studies}, author={Huili Li and Yongmei Liu and Ying Zhang and Dailong Fang and Bei Xu and L. L. Zhang and Tong Chen and Ke Ren and Yu Nie and Shaohua Yao and Xiang Rong Song}, journal={AAPS PharmSciTech}, year={2015}, volume={17}, pages={710-717} }